• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cardiol Therapeutics: A Leader in Research and Commercial Development of Pharmaceutical Cannabidiol Products and Targeted Therapies for Heart Failure and Cancer

    Alison Cameron
    Dec. 20, 2018 10:00AM PST
    Pharmaceutical Investing
    TSX:CRDL

    Cardiol Therapeutics Inc. (TSX:CRDL) has launched its campaign on the Investing News Network’s Life Science and Technology channels.

    Cardiol Therapeutics Inc. (TSX:CRDL) has launched its campaign on the Investing News Network’s Life Science and Technology channels.

    Cardiol is a biotechnology company focused on developing proprietary formulations that will treat some of the most life-threatening diseases in the western world. The Company is investigating targeting drugs to the heart to treat diastolic heart failure, including the use of highly purified pharmaceutically-manufactured cannabidiol (CBD).

    Cardiol is developing unique manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure. With this goal in mind, the company has formed exclusive partnerships with Noramco and Dalton Pharma Services, both of which are FDA-certified and working under GMP standards, to manufacture CBD at >99.5% purity and less than 10 ppm THC. These companies have been instrumental in developing Cardiol’s pharmaceutical CBD products and in working to produce them at scale. Through these partnerships, Cardiol plans to develop and commercialize one of the most advanced formulations of pharmaceutical CBD during 2019, leading a market that is now estimated to exceed $600 million in Canada alone.

    Cardiol Therapeutics’ company highlights include the following:

    • Implementing nanotechnologies to deliver CBD and other anti-inflammatory drugs for the treatment of diastolic heart failure.
    • Commercializing one of the most advanced formulations of pharmaceutical cannabidiol at >99.5% purity and less than 10 ppm THC during 2019 – a market estimated to exceed $600 million in Canada alone.
    • Research programs at the University of Alberta, the Houston Methodist DeBakey Heart & Vascular Center, and TecSalud del Tecnológico de Monterrey, Mexico.
    • Developing a combination therapy of cannabinoids and cell-based immunotherapies to improve the treatment of GBM.
    • Exclusive partnerships with Dalton Pharma Services and Noramco.
    • Management holds approximately 35 percent of the Company’s shares.

    Click here to see the educational profile for Cardiol Therapeutics Inc. (TSX:CRDL) and to request an investor presentation.

    cardiol therapeutics inc.pharmaceutical investingtsx:crdlheart failure
    The Conversation (0)

    Go Deeper

    AI Powered
    Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

    Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

    Cardiol Therapeutics (TSX:CRDL)

    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

    Latest News

    Cardiol Therapeutics
    Sign up to get your FREE

    Cardiol Therapeutics Investor Kit

    and hear about exciting investment opportunities.
    • Corporate info
    • Insights
    • Growth strategies
    • Upcoming projects

    GET YOUR FREE INVESTOR KIT

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×